Modeling for health care and other policy decisions: Uses, roles, and validity

Milton C. Weinstein, Edmond L. Toy, Eileen A. Sandberg, Peter J. Neumann, John S. Evans, Karen M. Kuntz, John D. Graham, James K. Hammitt

Research output: Contribution to journalArticlepeer-review

161 Scopus citations


The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The controversy stems in part from a misconception that the role of models is to establish truth rather than to guide clinical and policy decisions. In other domains of public policy that involve human life and health, such as environmental protection and defense strategy, models are generally accepted as decision aids, and many models have been formally incorporated into regulatory processes and governmental decision making. We formulate an analytical framework for evaluating the role of models as aids to decision making. Implications for the implementation of Section 114 of the Food and Drug Administration Modernization Act (FDAMA) are derived from this framework.

Original languageEnglish (US)
Pages (from-to)348-361
Number of pages14
JournalValue in Health
Issue number5
StatePublished - 2001

Bibliographical note

Funding Information:
This project was supported by a research grant from the International Federation of Pharmaceutical Manufacturers’ Associations. An earlier version of this paper was presented by Peter J. Neumann, ScD, at the Fourth Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Crystal City, VA, May 26, 1999.


  • Cost-effectiveness analysis
  • Models
  • Pharmacoeconomics
  • Validation


Dive into the research topics of 'Modeling for health care and other policy decisions: Uses, roles, and validity'. Together they form a unique fingerprint.

Cite this